Leponex 100 mg tabletes Letònia - letó - Zāļu valsts aģentūra

leponex 100 mg tabletes

mylan eood, bulgaria - klozapīns - tablete - 100 mg

Betaserc 24 mg tabletes Letònia - letó - Zāļu valsts aģentūra

betaserc 24 mg tabletes

mylan medical sas, france - betahistīna dihidrohlorīds - tablete - 24 mg

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Unió Europea - letó - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrela hidrohlorīds - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiskie līdzekļi - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Leponex 100 mg tabletes Letònia - letó - Zāļu valsts aģentūra

leponex 100 mg tabletes

mylan healthcare gmbh, germany - klozapīns - tablete - 100 mg

Leponex 100 mg tabletes Letònia - letó - Zāļu valsts aģentūra

leponex 100 mg tabletes

mylan eood, bulgaria - klozapīns - tablete - 100 mg

Calafos 750 mg košļājamās tabletes Letònia - letó - Zāļu valsts aģentūra

calafos 750 mg košļājamās tabletes

viatris limited, ireland - lantāns - košļājamā tablete - 750 mg

Dabigatran Etexilate Viatris 75 mg cietās kapsulas Letònia - letó - Zāļu valsts aģentūra

dabigatran etexilate viatris 75 mg cietās kapsulas

viatris limited, ireland - dabigatrāna eteksilāts - kapsula, cietā - 75 mg

Dabigatran Etexilate Viatris 150 mg cietās kapsulas Letònia - letó - Zāļu valsts aģentūra

dabigatran etexilate viatris 150 mg cietās kapsulas

viatris limited, ireland - dabigatrāna eteksilāts - kapsula, cietā - 150 mg

Betaserc 24 mg tabletes Letònia - letó - Zāļu valsts aģentūra

betaserc 24 mg tabletes

mylan ire healthcare ltd, ireland - betahistīna dihidrohlorīds - tablete - 24 mg

Betaserc 24 mg tabletes Letònia - letó - Zāļu valsts aģentūra

betaserc 24 mg tabletes

mylan medical sas, france - betahistīna dihidrohlorīds - tablete - 24 mg